Evidence map›Paper›PMID 31418056›Full record

Observational studyEuropean journal of clinical pharmacology2019

Breast cancer and spironolactone: an observational postmarketing study.

Pierre Sabatier, Jacques Amar, François Montastruc, Vanessa Rousseau, Leila Chebane, Béatrice Bouhanick, Jean-Louis Montastruc

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in European journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Pierre SabatierService de Pharmacologie Médicale et Clinique, Centre de PharmacoVigilance, de Pharmaco-épidémiologie et d'Informations sur le Médicament, CIC INSERM 1436, UMR INSERM 1027, Faculté de Médecine - Centre Hospitalier Universitaire, Toulouse, France.
Jacques AmarService Hypertension Artérielle et Thérapeutique, Centre Hospitalier Universitaire, UMR INSERM 1027, Toulouse, France.
François MontastrucService de Pharmacologie Médicale et Clinique, Centre de PharmacoVigilance, de Pharmaco-épidémiologie et d'Informations sur le Médicament, CIC INSERM 1436, UMR INSERM 1027, Faculté de Médecine - Centre Hospitalier Universitaire, Toulouse, France.
Vanessa RousseauService de Pharmacologie Médicale et Clinique, Centre de PharmacoVigilance, de Pharmaco-épidémiologie et d'Informations sur le Médicament, CIC INSERM 1436, UMR INSERM 1027, Faculté de Médecine - Centre Hospitalier Universitaire, Toulouse, France.
Leila ChebaneService de Pharmacologie Médicale et Clinique, Centre de PharmacoVigilance, de Pharmaco-épidémiologie et d'Informations sur le Médicament, CIC INSERM 1436, UMR INSERM 1027, Faculté de Médecine - Centre Hospitalier Universitaire, Toulouse, France.
Béatrice BouhanickService Hypertension Artérielle et Thérapeutique, Centre Hospitalier Universitaire, UMR INSERM 1027, Toulouse, France.
Jean-Louis MontastrucService de Pharmacologie Médicale et Clinique, Centre de PharmacoVigilance, de Pharmaco-épidémiologie et d'Informations sur le Médicament, CIC INSERM 1436, UMR INSERM 1027, Faculté de Médecine - Centre Hospitalier Universitaire, Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.ORCID http://orcid.org/0000-0001-6341-6001
Inserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRecent studies have discussed the risk of breast cancer with antihypertensive drugs. For spironolactone, data are conflicting. The present paper investigates this potential signal in VigiBase

methodsIn VigiBase

resultsDuring the study period, 125 ICSRs reported spironolactone exposure and breast malignant cancer in women ≥ 50 years. We failed to find a positive association between spironolactone exposure and breast cancer in comparison with exposure to other drugs (aROR = 0.63 95% CI [0.52-0.75]) or pseudo aldosterone antagonists (amiloride, triamterene) (0.56 [0.44-0.72]). Similar trends were found after exclusion of drug competitors and/or reports from health professionals.

conclusionThis study did not find evidence for breast cancer associated with spironolactone.

Indexed as

Adverse Drug Reaction Reporting SystemsAgedAged, 80 and overBreast NeoplasmsDiureticsFemaleHumansMiddle AgedOdds RatioProduct Surveillance, PostmarketingSpironolactoneDiureticsSpironolactoneAntialdosteroneBreast cancerSpironolactone

Identifiers

PMID31418056
OpenAlexW2968803517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.